
STAT News · Feb 23, 2026 · Collected from RSS
And other health news from the Morning Rounds newsletter
Theresa Gaffney is the lead Morning Rounds writer and reports on health care, new research, and public policy, with a particular interest in mental health, gender-affirming care, and LGBTQ+ patient communities. You can reach Theresa on Signal at theresagaff.97.Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. The Olympics are officially over, and while I didn’t watch much, I can’t stop thinking about Alysa Liu‘s free skate. Specifically the last minute or so, after all the big jumps are done, and she’s dancing and sliding on her knees across the ice. It’s exuberant. How drugmakers are navigating Trump’s FDA Historically, decisions made by the FDA about the drugs that Americans take have been largely shielded from political influence. “It was always the case: if it’s FDA, leave it alone,” one lobbyist recently told STAT’s Daniel Payne and Lizzy Lawrence. But under the Trump administration, the strategy is morphing, with an emphasis on “currying favor” with top administration officials, as another lobbyist put it. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe